Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Operating Leases (2018 - 2025)

Purple Biotech has reported Operating Leases over the past 5 years, most recently at $321000.0 for Q4 2022.

  • Quarterly Operating Leases fell 41.64% to $321000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $321000.0 through Dec 2022, down 41.64% year-over-year, with the annual reading at $321000.0 for FY2022, 41.64% down from the prior year.
  • Operating Leases was $321000.0 for Q4 2022 at Purple Biotech, down from $357000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $1.0 million in Q4 2020 and troughed at $8000.0 in Q2 2020.
  • The 5-year median for Operating Leases is $400000.0 (2018), against an average of $425384.6.
  • Year-over-year, Operating Leases tumbled 93.94% in 2020 and then skyrocketed 7462.5% in 2021.
  • A 5-year view of Operating Leases shows it stood at $400000.0 in 2018, then tumbled by 93.0% to $28000.0 in 2019, then surged by 3650.0% to $1.0 million in 2020, then crashed by 47.62% to $550000.0 in 2021, then crashed by 41.64% to $321000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Operating Leases are $321000.0 (Q4 2022), $357000.0 (Q3 2022), and $399000.0 (Q2 2022).